
## Elisabeth Vandenberghe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6095664/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. British Journal of Haematology, 1999, 105, 894-900.	1.2	229
2	The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 2002, 100, 3108-3114.	0.6	209
3	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 2020, 34, 2354-2363.	3.3	198
4	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematology,the, 2017, 4, e114-e126.	2.2	181
5	Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. British Journal of Haematology, 2003, 120, 793-800.	1.2	150
6	Translocation (11;14): A cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. Journal of Pathology, 1991, 163, 13-18.	2.1	113
7	Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. British Journal of Haematology, 2009, 144, 933-945.	1.2	80
8	Translocation t(6;9) occurring in acute myelofibrosis, myelodysplastic syndrome, and acute nonlymphocytic leukemia suggests multipotent stem cell involvement. Cancer Genetics and Cytogenetics, 1989, 42, 209-219.	1.0	43
9	BCR-ABL Transcript With an e19a2 (c3a2) Junction in Classical Chronic Myeloid Leukemia. Blood, 1997, 89, 3064-3064.	0.6	36
10	Riskâ€stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. British Journal of Haematology, 2013, 160, 640-648.	1.2	33
11	The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia. Cancer Research, 2009, 69, 8366-8375.	0.4	31
12	Large granular lymphocyte leukemia: natural history and response to treatment. Leukemia and Lymphoma, 2010, 51, 839-845.	0.6	31
13	Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leukemia Research, 2012, 36, 483-484.	0.4	31
14	CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2006, 47, 2371-2379.	0.6	28
15	Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop. European Journal of Cancer, 2008, 44, 366-373.	1.3	25
16	Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry. Laboratory Medicine, 2016, 47, 103-111.	0.8	22
17	Targeted nextâ€generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 161-163.	1.2	18
18	Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8 + invariant natural killer T cells. Clinical Immunology, 2017, 183, 91-98.	1.4	16

#	Article	IF	CITATIONS
19	dup(12)(q13→qter) in two t(14;18)-negative follicular b-non-hodgkin's lymphomas. Genes Chromosomes and Cancer, 1992, 4, 302-308.	1.5	13
20	Results of a multicentre <scp>UK</scp> â€wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma. British Journal of Haematology, 2018, 181, 555-559.	1.2	13
21	Rearrangements of immunoglobulin and TCR genes in lymphoid blast crisis of Ph + chronic myeloid leukaemia. British Journal of Haematology, 1990, 74, 414-419.	1.2	12
22	A Surviving Case of Acanthamoeba Granulomatous Amebic Encephalitis in a Hematopoietic Stem Cell Transplant Recipient. American Journal of Case Reports, 2020, 21, e923219.	0.3	10
23	The 5â€year followâ€up of a realâ€world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. British Journal of Haematology, 2021, 192, 1035-1038.	1.2	10
24	Acute Lymphoblastic Leukaemia with an e1a3 <i>BCR-ABL1</i> Fusion. Acta Haematologica, 2011, 126, 214-215.	0.7	9
25	Composite Blastoid Variant of Mantle Cell Lymphoma and Classical Hodgkin Lymphoma. International Journal of Surgical Pathology, 2017, 25, 281-286.	0.4	9
26	Translocation (14;19)(q32;q13.1) in a Young Patient who Developed a Large Cell Lymphoma after an Initial Diagnosis of CLL. Leukemia and Lymphoma, 1991, 5, 281-286.	0.6	8
27	T-lymphoblastic leukemia/lymphoma: a single center retrospective study of outcome. Leukemia and Lymphoma, 2010, 51, 1035-1039.	0.6	8
28	Case Study. International Journal of Gynecological Pathology, 2015, 34, 459-464.	0.9	8
29	Classical Hodgkin Lymphoma Arising Adjacent to a Breast Implant. International Journal of Surgical Pathology, 2016, 24, 448-455.	0.4	7
30	An immunophenotypic and molecular diagnosis of composite hairy cell leukaemia and chronic lymphocytic leukaemia. Medical Oncology, 2013, 30, 692.	1.2	6
31	Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms. Genetic Testing and Molecular Biomarkers, 2018, 22, 98-103.	0.3	6
32	Refractory recurrent ocular graft versus host disease. BMJ Case Reports, 2019, 12, e232579.	0.2	5
33	Cytogenetic characterization of three cases of unusual B-cell non-Hodgkin's lymphoma. Cancer Genetics and Cytogenetics, 1991, 53, 229-235.	1.0	4
34	Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study. Blood, 2018, 132, 707-707.	0.6	4
35	Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. Bone Marrow Transplantation, 2020, 55, 2335-2338.	1.3	3
36	FISH studies in DLBCL: correlations with cell of origin: the Irish experience. Journal of Clinical Pathology, 2018, 71, 947-948.	1.0	2

#	Article	IF	CITATIONS
37	Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay. Journal of Molecular Diagnostics, 2021, 23, 323-340.	1.2	2
38	NOTCH1 mutation in type II Hodgkin transformation of chronic lymphocytic leukemia. Leukemia and Lymphoma, 2017, 58, 732-735.	0.6	1
39	Potentially important miRNAs in enteropathy-associated T-cell lymphoma pathogenesis: A pilot study. Leukemia Research Reports, 2018, 10, 52-54.	0.2	1
40	Incidence of single hit Bcl-2 and Bcl-6 rearrangements in DLBCL: the Irish experience. Journal of Clinical Pathology, 2020, 73, 689-690.	1.0	1
41	Biclonal lymphoproliferative disorders: another association with NOTCH1-mutated chronic lymphocytic leukaemias. Irish Journal of Medical Science, 2020, 190, 1087-1094.	0.8	1
42	Impact and importance of a centralised review panel for lymphoma diagnostics in the WHO era: a single-centre experience. Journal of Clinical Pathology, 2019, 72, 506-509.	1.0	0
43	Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT. Blood, 2018, 132, 2070-2070.	0.6	0
44	Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia. Journal of Clinical Pathology, 2021, 74, jclinpath-2020-207246.	1.0	0